CureApp and Jichi Medical University Collaborate on a Hypertension Therapeutics App: Primary Endpoint Met in Phase III Clinical Trial in Japan
CureApp, Inc. (Head Office: Chuo-ku, Tokyo; CEO: Kohta Satake; hereafter “the Company”) has completed a Japanese Phase III multicenter randomized controlled trial of their digital therapeutics (“DTx”) app to treat hypertension, which was jointly researched by a team led by Professor Kazuomi Kario at Jichi Medical University. Results of this study showed a statistically significant difference in average systolic blood pressure*1 over a 24-hour period – the primary endpoint of this study, demonstrating a hypotensive effect. Moving forward, the Company will seek regulatory approval based on the results of this study.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210318005504/en/
CureApp and Jichi Medical University collaborate on a hypertension therapeutics app: Primary endpoint met in Phase III clinical trial in Japan (Graphic: Business Wire)
Summary of the clinical trial and efficacy of the hypertension therapeutics app
Commencing in December 2019, this trial*2 evaluated the efficacy and safety of the DTx app when used with patients with essential hypertension who had not received oral treatments using antihypertensive drugs. For this comparative study, subjects were divided into two groups. This included a control group that only applied lifestyle changes based on the Guidelines for the Management of Hypertension 2019 (hereafter, “the Guidelines”)*3, and an intervention group using the DTx app in addition to the lifestyle changes proposed in the Guidelines.
As a result, the intervention group showed a statistically significant difference from the control group in the “deviation from the baseline in the average systolic blood pressure over a 24-hour period as measured by ambulatory blood pressure monitoring (ABPM)*4 in the 12th week of the study” – the primary endpoint. This demonstrates that the DTx app had a marked effect in treating hypertension. The results from this study will be presented in detail at conferences and in papers at a later date to be notified separately.
The potential of therapeutics for hypertension
Hypertension is the highest risk factor for cerebral and cardiovascular diseases (stroke and heart disease). An estimated 100,000 people*5 die of hypertension-induced cerebral and cardiovascular diseases every year. In Japan, hypertension is found in some 43 million people*3, and medical costs associated with hypertension have ballooned to around 1.7 trillion yen*6. Despite this, only around 10 million people*7 are said to receive continuous treatment for hypertension, less than one-quarter of the total affected.
While lifestyle improvements are vital for treating hypertension, maintaining such changes is dependent on a patient’s values and motivation, their workplace and home environment, and other factors. This presents challenges for effective intervention by medical institutions. There is also a subset of patients that wish to avoid medication who struggle with reducing their blood pressure. In response to these issues, this DTx app automatically delivers treatment guidance personalized to the individual (optimal nutritional, exercise, and sleeping advice based on an IoT blood pressure monitor and lifestyle habit logs, and notifications prompting behavioral changes) directly to the patient. This form of treatment helps reduce hypertension without the use of medication by encouraging changes in mindset and behavior, and aiding patients in adopting appropriate lifestyle habits.
*1 Systolic blood pressure: High blood pressure measured in blood pressure measurements.
*2 Kario K. Nomura A. Satake K. et al. A multicenter clinical trial to assess the efficacy of the digital therapeutics for essential hypertension: Rationale and design of the HERB-DH1 trial. J Clin Hypertens. (Greenwich) 2020;22(9):1713-1722 https://doi.org/10.1111/jch.13993
*3 Guidelines for the Management of Hypertension 2019 [JSH2019]; The Japanese Society of Hypertension (2019) https://www.jpnsh.jp/guideline.html
*4 Ambulatory blood pressure monitoring (ABPM): Continuous blood pressure measurements taken at predetermined intervals over a 24 hour period during the course of one’s daily life. This helps determine variations in blood pressure (variation patterns over the course of a day). This is important due to the various factors which may alter one’s blood pressure.
*5 “Vital Statistics Summary”2019 Study (Ministry of Health, Labour and Welfare)
*6 “Medical Care Expenditure Summary” 2018 Study (Ministry of Health, Labour and Welfare)
*7 “Patient Study”2017 Study (Ministry of Health, Labour and Welfare)
Department of Cardiovascular Medicine, Jichi Medical University
Professor Kazuomi Kario
The fact that the world’s first hypertension therapeutics app was able to produce a hypotensive effect with relation to the average systolic blood pressure over a 24-hour period – a key evaluation item of this Phase III clinical study (trial) – represents a significant step forward for hypertension treatment. When treating hypertension, reducing the risk of serious complications through therapeutic intervention and reducing blood pressure at an early stage is vital. Treatment is based on reducing salt intake and maintaining a proper weight, getting sufficient exercise and sleep, and other lifestyle changes. The digital hypertension treatment that this DTx app provides through the use of an advanced bidirectional algorithm represents a new field for hypertension treatment, and is expected to play a pivotal role in providing medical care tailored to the individual, and in promoting drug-free treatments that do not rely on medications.
Kohta Satake, CEO and Practicing Doctor
We have expanded our focus to encompass algorithm development to provide personalized healthcare advice based on medical evidence. The more data provided by the patient, the more the advice given is specifically tailored to the patient’s condition. We view the popularization of digital therapeutics for hypertension as having the potential to alter hypertension treatments for the better, as well as greatly contribute to reducing medical care expenses. Following our nicotine dependency therapeutic app “CureApp SC”, which was the first app of its kind to be covered by insurance in Japan, we also look to receive regulatory approval and insurance coverage for our hypertension therapeutics app.
About CureApp, Inc.
CureApp, Inc. is a MedTech venture that conducts research and development into the creation of medical device programs which apply advanced software technology and medical evidence to treat illnesses, with the intent of manufacturing and distributing them. We are hard at work developing “digital therapeutics” - apps used to treat illnesses - in order to become the first in Japan to establish a new healthcare service centered on “creating new therapeutic effects through technology.” In August 2020, the nicotine dependency treatment app and CO checker, “CureApp SC,” became the first therapeutic app to receive regulatory approval in Japan, and prescriptions began as a treatment covered by insurance in December of the same year.
In addition to the hypertension therapeutic app, we are currently pursuing research and development into various other digital therapeutics apps. These include a nonalcoholic steatohepatitis (NASH) therapeutic app jointly developed and currently undergoing clinical trials with the University of Tokyo Hospital, joint research on an app with the National Hospital Organization Kurihama Medical and Addiction Center, and a patient support app for cancer patients being jointly developed with DAIICHI SANKYO COMPANY, LIMITED.
We also draw upon the knowledge accumulated through the development of these therapeutic apps for medical institutions to provide the “ascure Smoking Cessation Program” for corporations that have been implemented at over 200 companies, health insurance associations and local municipalities.
Moving forward, we will look to sequentially roll out this Japanese-developed digital therapeutics solution worldwide.
[CureApp, Inc. Company Profile]
Representative Director and CEO: Kohta Satake
Head office: Kodenma-Cho YS building 4F, 12-5, Nihonbashi Kodenma-Cho, Chuo-ku, Tokyo, Japan
Business description: Development of medical device programs, mobile health-related services
[Jichi Medical University Overview]
Name: Jichi Medical University
Representative: Director, Toshio Oishi
Address: 3311-1 Yakushiji, Shimotsuke-shi, Tochigi-ken, Japan
[For research inquiries]
Department of Cardiovascular Medicine, Jichi Medical University
Professor Kazuomi Kario
Ph: +81 285-58-7538 E-mail: firstname.lastname@example.org
[For inquiries regarding therapeutics apps]
PR Representative, Yuuki Mishima
Ph: +81 3-6231-0183 E-mail: email@example.com
About Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Former Flex Executive Paul Humphries Joins Westfall Technik’s Board of Directors19.4.2021 03:19:00 CEST | Press release
Westfall Technik Inc. has added industry veteran Paul Humphries to its board of directors. Humphries worked with Westfall CEO Brian Jones and COO Mark Gomulka while at NASDAQ-listed Flex Ltd. (formerly Flextronics), and he has three decades of experience leading outsourced manufacturing services businesses. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210418005057/en/ Paul Humphries, a former long-time, senior Flex executive, brings a wealth of experience to Westfall's board. He has spent years in the medical industry building global, high-reliability businesses. (Photo: Business Wire) Until his retirement in November 2020, Humphries spent two decades at Flex, the 160,000-employee, Singapore-based, multinational electronics contract manufacturer. In his most recent role at Flex, Humphries served as president for its High Reliability Solutions (HRS) unit, which generated $11 billion in annual revenue and served the medical,
NielsenIQ and J.D. Power Enter Strategic Alliance to Bring Unparalleled Automotive Research to Major Growth Markets19.4.2021 03:00:00 CEST | Press release
NielsenIQ, an industry leader in global measurement, and J.D. Power, a global leader in data analytics and consumer intelligence, today announced their intent to launch a multinational strategic alliance to bring benchmark automotive customer experience studies and deep auto industry data analysis to major growth markets such as India, Southeast Asia and the Middle East. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210418005017/en/ Drawing on the strong market presence of NielsenIQ and the deep industry expertise of J.D. Power, the alliance will feature J.D. Power benchmark automotive studies, recognized as the gold standard in the automotive industry, complemented by NielsenIQ’s new digital and technology-based platforms and value-added services like social listening analysis. Combining NielsenIQ and J.D. Power capabilities will allow automotive sector clients to strategize for the future based on data-driven tools and in
Leading European Football Clubs Announce Participation in New Super League Competition19.4.2021 00:22:00 CEST | Press release
Twelve of Europe’s leading football clubs have today come together to announce they have agreed to establish a new mid-week competition, the Super League, governed by its Founding Clubs. AC Milan, Arsenal FC, Atlético de Madrid, Chelsea FC, FC Barcelona, FC Internazionale Milano, Juventus FC, Liverpool FC, Manchester City, Manchester United, Real Madrid CF and Tottenham Hotspur have all joined as Founding Clubs. It is anticipated that a further three clubs will join ahead of the inaugural season, which is intended to commence as soon as practicable. Going forward, the Founding Clubs look forward to holding discussions with UEFA and FIFA to work together in partnership to deliver the best outcomes for the new League and for football as a whole. The formation of the Super League comes at a time when the global pandemic has accelerated the instability in the existing European football economic model. Further, for a number of years, the Founding Clubs have had the objective of improving th
Advanced Eye Protection Against Covid-19 For Healthcare Professionals – an Exclusive Bollé Safety Technology16.4.2021 22:00:00 CEST | Press release
Bollé Safety, world leader in the design and manufacture of protective eyewear, presents its Healthcare division dedicated to all healthcare professionals. Its range of protective eyewear with anti-fog and anti-scratch PLATINUM® coating provides highly exposed employees with the highest levels of protection, clarity, and vision. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210416005009/en/ @BolléSafety - A.Childeric Viruses & infections’ protection Bollé Safety offers certified products compliant with the most stringent international standards. Its anti-fog PPE product range is tailored to protect professionals who are at high risk of being exposed to bodily fluids when providing care to patients. It is the company’s shared commitment to provide the highest quality protection for all healthcare workers. The importance of a clear vision Bollé Safety’s unique and exclusive permanent double sided anti-fog and anti-scratch PLA
Zeepay Ghana Acquires Mangwee Mobile Money in Zambia16.4.2021 19:55:00 CEST | Press release
Zeepay, the leading African Challenger Fintech with operations in over 10 African countries today acquired a 51 percent stake in Mangwee Mobile Money in Zambia. In a private placement Zeepay and Mangwee agreed to a sale of 51 percent of Mangwee shares to Zeepay. The deal makes Zeepay Ghana the majority shareholder of the entity. Mangwee has been in operations since 2018, and was initially set up to operate as an alternative wallet targeting university students in Zambia with the aim of assisting to drive the cost of mobile money services downward. Zeepay is the leading African challenger fintech with operations across 20 African countries and 30 day active in 10 of them. The company specializes in paying remittances into mobile money wallets across Africa and is regulated by both Bank of Ghana as an EMI issuer and in the UK as a Money Transfer Operator, by the Financial Conduct Authority. The merger is the first of its kind; that two Indigenous African fintechs into Mobile Money operat
CGTN: Leading With Action: China in the Fight for Carbon-Neutral Future16.4.2021 18:29:00 CEST | Press release
Climate change is not taking a break from wreaking havoc in 2020, with the joint highest global temperatures on record, rampant bushfires, the faster rates of sea level rise and the extinction of some species. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210416005435/en/ Under this circumstance, Chinese President Xi Jinping, French President Emmanuel Macron, and German Chancellor Angela Merkel held a virtual meeting Friday on climate change, ahead of the Leaders' Climate Summit on Earth Day convened by the U.S., scheduled next week. Emphasizing that he always advocates building a community with a shared future for mankind, the Chinese president voiced his willingness to strengthen cooperation with France and Germany on climate change. "Tackling climate change is a common cause for all mankind and it should not become a geopolitical bargaining chip, a target for attacking other countries, or an excuse for trade barriers," h
Colicity Inc. Announces the Separate Trading of its Class A Common Stock and Warrants, Commencing on or about April 16, 202116.4.2021 15:30:00 CEST | Press release
Colicity Inc. (the “Company”) announced that holders of the units sold in the Company’s initial public offering of 34,500,000 units, including the underwriters’ exercise of their full over-allotment option for 4,500,000 units, completed on February 26, 2021 (the “Offering”) may elect to separately trade the Class A common stock and warrants included in the units commencing on or about April 16, 2021. Any Units not separated will continue to trade on The Nasdaq Capital Market under the symbol “COLIU,” and the Class A common stock and warrants will separately trade on The Nasdaq Capital Market under the symbols “COLI” and “COLIW,” respectively. No fractional warrants will be issued upon separation of the units and only whole warrants will trade. Holders of units will need to have their brokers contact Continental Stock Transfer & Trust Company, the Company’s transfer agent, in order to separate the units into Class A common stock and warrants. This press release shall not constitute an o